• Home
  • Search Results

Search Results

Older Adult (65+)
Cancer
385 studies match your search
Open

Study of Camizestrant in ER Positive, HER2 Negative, Early-Stage High Risk Breast Cancer.

Have you been diagnosed with breast cancer and completed your surgery? Has your doctor recommended hormonal therapy to help prevent your cancer from returning? You may be able to participate in a research study of a new drug called Camizestrant. Please reach out to the research team if you are interested and we will provide information regarding the next steps.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

Study of CAR-T cells in patients with recurrent epithelial ovarian, peritoneal, or fallopian tube cancer

Do you have ovarian, peritoneal, or fallopian tube cancer that came back after receiving standard therapy? If so, you might be able to take part in a study that looks at a new treatment, iC9.CAR.B7-H3 cells, to test the safety of these cells and observe any side effects.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Ovarian)
Open

Harnessing Analysis RNA expression and Molecular subtype to Optimize Novel TherapY MBCA

This study is for patients diagnosed with breast cancer that has spread to other parts of the body, which is called Metastatic Breast Cancer. This study will look at information from your tumor that may help choose treatments. Researchers will use this information to find out how different patients may respond to different treatments, leading to better treatments for future patients. You may not benefit personally, but your doctor may be given information which may help guide your treatments.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Breast)
Visit Location
100% Remote (online, phone, text)
Open

Leukemia Treatment Study

Are you 18 or older? Have you recently received a diagnosis of acute myeloid leukemia (AML) with certain gene changes? If you answered yes to both, you may be able to participate in an AML treatment study. We want to understand the effectiveness of the combination of a new anti-cancer drug called SNDX-5613 and the standard chemotherapy treatment.

Age & Gender
  • 18 years ~ 75 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Open

Biomarker analysis of breast cancer patients receiving immunotherapy

You are being asked to participate in this research study because you have been diagnosed with breast cancer and considered for immunotherapy. This study will investigate your response to immunotherapy.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Breast)
Open

Triple Negative Breast Cancer (TNBC) T Cell Study

Do you have triple-negative breast cancer that either came back or did not improve after initial cancer treatment? If so, you may be able to take part in this gene therapy research study to learn more about using your own modified immune cells as a possible treatment.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

Get Real and Heel: Cancer and Exercise Registry Study

Are you interested in improving your physical health and wellbeing during or after cancer treatment? If so, our free 12- week exercise program might be a good fit for you! We are creating a registry of adults with a cancer diagnosis who have gone through our program.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 19 more)
  • Wellness and Lifestyle
  • Movement
Open

Adults with Blood Cancer

Have you been diagnosed with Blood Cancer. If so, you may be able to take part in a research study looking at the safety of giving a new drug called AZD9829 to patients with Leukemia.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Open

Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab

Can we extend your life after the diagnosis of your cancer in the stomach, esophagus, or gastroesophageal junction by adding a third chemotherapy drug to the usual combination of two chemotherapy drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for treatment of your cancer in the stomach, esophagus, or gastroesophageal junction. The usual approach is defined as care most people get for cancer in the stomach, esophagus, or gastroesophageal junction.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Stomach and Esophageal)
Open

Advanced Melanoma Tumor Study

Do you have an advanced melanoma tumor and have received prior systemic therapy? Has your cancer progressed on the other treatments? If so, the you may be able to take part in a study to help us learn the safety and dosage of the drug AB248 on solid tumors.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Melanoma)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research